Simultaneous quantification of d- vs. l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: Differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents

Gobert, Alain P.; Rivet, Jean‐Michel; Billiras, Rodolphe; Parsons, Francesca; Millan, Mark J.

doi:10.1016/j.jneumeth.2011.08.040

Cited by 17 publications

(35 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described elsewhere Gobert et al, 2003Gobert et al, , 2011, male rats (200 -250 g) were implanted: 1) in the FCX (AP, ϩ2.2 from bregma; ML, ϩ0.6 or Ϫ0.6; DV, Ϫ0.2 from dura) with a guide cannula for quantification of monoamines, ACh, or amino acids; 2) in the ventral hippocampus (AP, Ϫ5.3; ML, ϩ5.0 or Ϫ5.0; DV, Ϫ3.2 from dura) with a guide cannula for quantification of monoamines; or 3) in the nucleus accumbens (AP, ϩ0.8 from bregma; ML, ϩ0.6; DV, Ϫ4.5 from dura) and the striatum (AP, ϩ0.5 from bregma; ML, Ϫ2.8; DV, Ϫ3.0 from dura) with two guide cannulae for quantification of DA and 5-HT. Animals were then single-housed and permitted to recover for 5 days.…”

Section: Methodsmentioning

confidence: 99%

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α₂-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

Dekeyne¹,

Brocco²,

Loiseau³

et al. 2011

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

The present studies characterized the functional profile of N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo-[e]indole-3-carboxamide) (S32212), a combined serotonin (5-HT) 2C receptor inverse agonist and ␣ 2 -adrenoceptor antagonist that also possesses 5-HT 2A antagonist properties (J Pharmacol Exp Ther 340: [750][751][752][753][754][755][756][757][758][759][760][761][762][763][764] 2012). Upon parenteral and/or oral administration, dosedependent (0.63-40.0 mg/kg) actions were observed in diverse procedures. Both acute and subchronic administration of S32212 reduced immobility time in a forced-swim test in rats. Acutely, it also suppressed marble burying and aggressive behavior in mice. Longterm administration of S32212 was associated with rapid (1 week) and sustained (5 weeks) normalization of sucrose intake in rats exposed to chronic mild stress and with elevated levels of mRNA encoding brain-derived neurotrophic factor in hippocampus and amygdala (2 weeks). S32212 accelerated the firing rate of adrenergic perikarya in the locus coeruleus and elevated dialysis levels of noradrenaline in the frontal cortex and hippocampus of freely moving rats. S32212 also elevated the frontocortical levels of dopamine and acetylcholine, whereas 5-HT, amino acids, and histamine were unaffected. These neurochemical actions were paralleled by "promnemonic" properties: blockade of scopolamine-induced deficits in radial maze performance and social recognition and reversal of delay-induced impairments in social recognition, social novelty discrimination, and novel object recognition. It also showed anxiolytic actions in a Vogel conflict procedure. Furthermore, in an electroencephalographic study of sleep architecture, S32212 enhanced slowwave and rapid eye movement sleep, while decreasing waking. Finally, chronic administration of S32212 neither elevated body weight nor perturbed sexual behavior in male rats. In conclusion, S32212 displays a functional profile consistent with improved mood and cognitive performance, together with satisfactory tolerance.

show abstract

Section: Methodsmentioning

confidence: 99%

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α₂-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

Dekeyne¹,

Brocco²,

Loiseau³

et al. 2011

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Readouts employed like extracellular glutamate levels, stimulus-evoked electrophysiological responses and circuit neuroimaging can all be translationally performed in humans (Burckholtz and Meyer-Lindenberg, 2014;English et al, 2014;Gobert et al, 2011;Poels et al, 2014).…”

Section: Enriching the Repertoire Of Behavioural Readouts: Integratinmentioning

confidence: 99%

Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders

Millan¹,

Goodwin²,

Meyer‐Lindenberg³

et al. 2015

European Neuropsychopharmacology

Self Cite

112

View full text Add to dashboard Cite

“…[12][13][14][15] In addition, we observed the 5-FU dose-dependent (0 to 125 mg of 5-FU per kg body weight) reduction of brain taurine concentrations in rats (unpublished data). Lahiri and associates reported the reduction of brain alanine production after fluoroacetate administration.…”

Section: Discussionmentioning

confidence: 64%

“…Alanine is produced by reductive amination of pyruvate and associated with glycolysis, and taurine has osmoregulatory, antioxidant, and membrane-stabilizing properties and can influence cognition. 15 Metabolites associated with 5-FU catabolism, specifically fluoroacetate and fluorocitrate, have been shown to affect metabolic pathways related to alanine and taurine in the brain.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have demonstrated that 5-FU catabolites, particularly fluoroacetate and fluorocitrate, affect metabolic pathways related to alanine and taurine metabolism in the brain. [12][13][14][15] According to our premise, the correction technique would sensitively detect the difference in brain metabolite concentrations between these 2 groups of rats.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Recovery Correction Technique for NMR Spectroscopy of Perchloric Acid Extracts using DL-valine-2,3-d2: Validation and Application to 5-Fluorouracil-induced Brain Damage

Nakagami¹,

Yamaguchi²,

Ezawa

et al. 2014

magn reson med sci

View full text Add to dashboard Cite

Purpose: We explored a recovery correction technique that can correct metabolite loss during perchloric acid (PCA) extraction and minimize inter-assay variance in quantitative 1 H nuclear magnetic resonance (NMR) spectroscopy of the brain and evaluated its efficacy in 5-fluorouracil (5-FU)-and saline-administered rats.Methods: We measured the recovery of creatine and DL-valine-2,3-d 2 from PCA extract containing both compounds (0.5 to 8 mM). We intravenously administered either 5-FU for 4 days (total, 100 mg/kg body weight) or saline into 2 groups of 11 rats each. We subsequently performed PCA extraction of the whole brain on Day 9, externally adding 7 µmol of DL-valine-2,3-d 2 . We estimated metabolite concentrations using an NMR spectrometer with recovery correction, correcting metabolite concentrations based on the recovery factor of DL-valine-2,3-d 2 . For each metabolite concentration, we calculated the coefficient of variation (CEV) and compared differences between the 2 groups using unpaired t-test.Results: Equivalent recoveries of DL-valine-2,3-d 2 (89.4 « 3.9%) and creatine (89.7 « 3.9%) in the PCA extract of the mixed solution indicated the suitability of DL-valine-2,3-d 2 as an internal reference. In the rat study, recovery of DL-valine-2,3-d 2 was 90.6 « 9.2%. Nine major metabolite concentrations adjusted by recovery of DL-valine-2,3-d 2 in saline-administered rats were comparable to data in the literature. CEVs of these metabolites were reduced from 10 to 17% before to 7 to 16% after correction. The significance of differences in alanine and taurine between the 5-FU-and salineadministered groups was determined only after recovery correction (0.75 « 0.12 versus 0.86 « 0.07 for alanine; 5.17 « 0.59 versus 5.66 « 0.42 for taurine [µmol/g brain tissue]; P < 0.05).Conclusion: A new recovery correction technique corrected metabolite loss during PCA extraction, minimized inter-assay variance in quantitative 1 H NMR spectroscopy of brain tissue, and effectively detected inter-group differences in concentrations of brain metabolites between 5-FU-and saline-administered rats.

show abstract

Simultaneous quantification of d- vs. l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: Differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents

Cited by 17 publications

References 113 publications

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α₂-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α₂-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders

Recovery Correction Technique for NMR Spectroscopy of Perchloric Acid Extracts using DL-valine-2,3-d2: Validation and Application to 5-Fluorouracil-induced Brain Damage

Contact Info

Product

Resources

About

Simultaneous quantification of d- vs. l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: Differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents

Cited by 17 publications

References 113 publications

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders

Recovery Correction Technique for NMR Spectroscopy of Perchloric Acid Extracts using DL-valine-2,3-d2: Validation and Application to 5-Fluorouracil-induced Brain Damage

Contact Info

Product

Resources

About

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α₂-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α₂-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization